Kringle 5 (K5) of human plasminogen has been shown to inhibit angiogenesis by inducing the apoptosis of proliferating endothelial cells. Peptide regions around the lysine-binding pocket of K5 largely mediate these effects, particularly the peptide PRKLYDY, which we show to compete with K5 for the binding to endothelial cells. The cell surface binding site for K5 that mediates these effects has not been defined previously. Here, we report that glucose-regulated protein 78, exposed on cell surfaces of proliferating endothelial cells as well as on stressed tumor cells, plays a key role in the antiangiogenic and antitumor activity of K5. We also report that recombinant K5-induced apoptosis of stressed HT1080 fibrosarcoma cells involves enhanced activity of caspase-7, consistent with the disruption of glucose-regulated protein 78-procaspase-7 complexes. These results establish recombinant K5 as an inhibitor of a stress response pathway, which leads to both endothelial and tumor cell apoptosis. (Cancer Res 2005; 65(11): 4663-72) 
Introduction
Angiogenesis in normal tissues is tightly regulated by a balance between angiogenesis stimulators, such as vascular endothelial growth factor (VEGF), and angiogenesis inhibitors, such as thrombospondin-1 (1) (2) (3) (4) (5) . Tumors, such as benign neoplasias, remain dormant when the proangiogenic and antiangiogenic factors are balanced (6) (7) (8) (9) . However, when a tumor outgrows its blood supply, local hypoxia increases the production of angiogenesis stimulators and decreases the production of angiogenesis inhibitors. This proangiogenic switch releases a tumor from dormancy and drives tumor progression (10) (11) (12) .
Several endogenous angiogenesis inhibitors are protein fragments derived from extracellular matrix (13) or hemostatic system proteins (14) . Plasminogen is a blood protein that is proteolysed into potent angiogenesis inhibitors, such as angiostatin (kringles 1-4) and kringle 5 (K5; refs. [15] [16] [17] . Kringle domains contain f80 amino acids and three similarly linked disulfide bonds (18) . Recombinant K5 (rK5) displays the most potent inhibitory activity to endothelial cell proliferation and migration (19) (20) (21) of known naturally occurring angiogenesis inhibitors. A recombinant K5 has also been shown to induce apoptosis in proliferating endothelial cells (19) . Recently, reports show that rK5 prevents the development and arrests the progression of ischemia-induced retinal neovascularization in a rat model (21) by the down-regulation of VEGF and upregulation of pigment epithelial-derived factor.
The tertiary structure of K5 has been studied in detail and contains a weak lysine-binding pocket. By contrast, the endothelial-binding site through which the antiangiogenic effects of K5 are mediated has not been defined (22) . Here, we report that the antiangiogenic and proapoptotic activity of rK5 depends on a high-affinity binding interaction with glucose-regulated protein 78 (GRP78) exposed on the surface of stimulated endothelial cells and on many hypoxic and cytotoxic stressed tumor cells. Peptide synthesis. All peptides were synthesized using a Symphony (Protein Technology, Inc., Woburn, MA) automated peptide synthesizer. Peptide purification was done using a Gilson high-performance liquid chromatography system equipped with automated liquid handler. The Fmoc-protected amino acids and resins were purchased either from Calbiochem-Novabiochem Corp. (San Diego, CA) or from Bachem, Inc. (Torrance, CA). Mass spectra were recorded using either a Finnigan SSQ7000 (ESI) or JEOL JMS-SX102A-Hybrid (FAB) mass spectrometers.
Materials and Methods
Cell proliferation assay. The effect of rK5 and rK5 peptides on endothelial cells was assessed using a proliferation assay with 1% bovine serum albumin (BSA) and 3 ng/mL bFGF in serum-free medium. Relative cell numbers in each well of a 96-well microplate after incubation for 72 hours in the absence or presence of inhibitors were determined by using the AQueous Cell Proliferation Assay (Promega, Madison, WI). For all other cell lines tested for proliferation, minimal growth medium was used (16) . Results are presented as the percent inhibition of control cell (bFGFinduced) proliferation.
Expression and purification of recombinant kringle 5. K5 fragment was PCR amplified from a human plasminogen cDNA template (American Type Culture Collection) with the following two primers: 5V -CTGCTTCCAGATAGAGA-3V ( forward primer for residues 450-457) and 5V -TTATTAGGCCGCACACTGAGGGA-3V (reverse primer for residues 538-543). The PCR fragment was ligated into the pET32a vector (Novagen, San Diego, CA) that had been digested with NcoI and XhoI. The NcoI and XhoI cleavage sites of the pET32a had been filled in to form blunt ends with plaque-forming unit DNA polymerase (2.5 units/AL, Stratagene, La Jolla, CA). XL2-Blue ultracompetent cells (Stratagene) were transformed with the ligation mixture as per the manufacturer's instructions. After sequence confirmation, the pET32a/K5 vector was retransformed into Escherichia coli BL21 cells (DE3, Novagen) for expression as per the manufacturer's instructions. The recombinant protein was recovered from the cell paste by cell lysis in lysis buffer [50 mmol/L Tris, 300 mmol/L NaCl, 1 mmol/L MgCl 2 (pH 7.8)] using a French press. The His-tagged protein was purified over a Probond nickel resin (Invitrogen). The His tag was removed from the rK5 molecule by enterokinase (Invitrogen) and the rK5 was repurified over a second Probond nickel column to remove the His tag. Finally, endotoxin contamination was removed by size filtration (5 kDa) chromatography.
Yeast rK5 was expressed as described previously (22) . Briefly, the human K5 gene was expressed in the methylotrophic yeast Pichia pastoris (Invitrogen). Genetic transcription of rK5 was under the control of the alcohol oxidase promoter (AOX1). The AOX1 promoter permits high-level expression of heterologous proteins in Pichia. The K5 expression construct also includes a secretion signal sequence to direct transport of the protein to the medium. The plasmid construct was a hybrid of commercially available plasmid sequences from Invitrogen, designated pHIL-S1 and pHIL-D2. The expressed rK5 was purified by octyl-Sepharose and size exclusion chromatography.
Radiolabeled recombinant kringle 5. rK5 was tritiated ( 3 H) by a method published previously (23) Briefly, a carefully controlled particle beam composed of T3+ and T2+ ions and fast T2 molecules were accelerated into rK5 within a vacuum chamber. The 3 HK5 was found to be active in the endothelial cell migration assay with an IC 50 of 0.2 nmol/L and a specific activity of 8.74 mCi/mg.
Human rK5 potency is highly dependent on the extent of iodination because the molecule contains a readily iodinated tyrosine in its binding sequence. Mutations of this tyrosine to phenylalanine resulted in incorrect protein folding. However, dog rK5 has a phenylalanine in this position naturally and is folded and active in our assays. We therefore relied on 125 IrK5 (dog) as a reagent. The radioiodination of rK5 (dog) was done following the procedure published by Markwell (24) . The Iodobead reagent (Pierce, Rockford, IL) was used for the radioiodination and the labeling reaction as per protocol. A total of two beads were used with 25 Ag rK5 for the reaction. The separation of labeled rK5 from free iodine was accomplished using an iodine trap and a desalting spin filter (Pierce). 125 IK5 (dog) was found to be activity in the migration assay.
Endothelial cell migration assays. The effect of rK5 on endothelial cell migration was determined by two different methods. The first assay was done in a 96-well plate with a cellulose membrane between the upper and the lower chambers. HMVECs were starved of growth factors overnight, labeled with fluorescent calcein AM (50-100 nmol/L), plated into a 96-well migration chamber (2.9 Â 10 4 per well, Neuroprobe), and stimulated to migrate with VEGF (5 ng/mL). After 4 hours, migrated cells were measured by fluorescence (25) . In a second assay for cellular migration, a standard Boyden chamber was used (26) . HMVEC cells were starved overnight in DMEM containing 0.1% BSA and harvested by scraping and resuspended in DMEM with 0.1% BSA at 1.5 Â 10 6 cells/mL. Cells were added to the bottom of a 48-well Boyden chamber. The chamber was assembled and inverted, and cells were allowed to attach for 2 hours at 37jC to polycarbonate chemotaxis membranes (5 Am pore size) that had been soaked in 0.1% gelatin overnight and dried. The chamber was reinverted, test substances, including activators, were added to the wells of the upper chamber, and the apparatus was incubated for 4 hours at 37jC. Growth factors were used, where indicated, at concentrations determined in preliminary experiments to give equivalent migration responses of f100 cells migrated per highpower field (Â400). Growth factors and concentrations used were acidic FGF (aFGF; 50 ng/mL), bFGF (15 ng/mL), interleukin-8 (IL-8; 40 ng/mL), transforming growth factor-h (TGF-h; 1 pg/mL), VEGF (100 pg/mL), hepatocyte growth factor (HGF; 40 ng/mL), and platelet-derived growth factor (PDGF; 250 pg/mL). Membranes were recovered, fixed, and stained and the number of cells that had migrated to the upper chamber per 10 high-power fields was counted. Background migration to DMEM plus 0.1% BSA was subtracted and the data were reported as the number of cells migrated per 10 high-power fields (Â400) or, when results from multiple experiments were combined, as the percent inhibition of migration compared with the positive growth factor control (26) .
Assessment of cellular apoptosis. The effects of rK5 and rK5 peptideinduced apoptosis were determined with a histone ELISA apoptosis assay (Roche, Indianapolis, IN; ref. 27); 5,000 cells per well were grown in 96-well plates. rK5 and/or an antibody to GRP78 were added to plates and incubated overnight. Apoptosis was determined from triplicate samples and the apoptotic index was determined by dividing the absorbance from the treated cells by the absorbance from the untreated cells.
Binding of human recombinant kringle 5 to endothelial cells. Tritium-labeled rK5 was added to monolayers of 50,000 HMVEC cells that were either starved or stimulated for 16 hours by 15 ng/mL bFGF and 5 ng/mL VEGF in 96-well plates. The number of counts remaining bound to the cells after extensive washing determined the total amount of rK5 bound (28) .
Binding of 125 I kringle 5 (dog) to endothelial cells and recombinant kringle 5 to recombinant glucose-regulated protein 78. The same methods as described above for the expression and purification of human K5 were used to express dog rK5 in E. coli. Immunohistochemical analysis of glucose-regulated protein 78 on human microvascular endothelial cells. Cells were starved overnight with medium alone. Complete medium, containing 10% fetal bovine serum plus 15 ng/mL bFGF and 5 ng/mL VEGF, was added at different times to the cells. GRP78 bound antibody was visualized with horseradish peroxidase (HRP)-reactive substrate visualized by a brown color.
Binding and pull-down of recombinant kringle 5 binding proteins. Binding of rK5 to endothelial cells was measured as described (29) . Briefly, HMVEC cells (50,000 per well) were cultured in 96-well microtiter plates for 2 hours, washed, and then incubated with PBS and increasing concentrations of 3 HK5 or 125 IK5 (dog) for another 2 hours at 4jC. After washing, cells were lysed and bound labeled rK5 was counted.
Cell surface rK5 binding proteins were isolated by two methods. The first method used NH 2 -terminal biotinylated PRKLYDY active site rK5 peptide with 5 Â 10 7 endothelial or tumor cell lysates. Cell lysate was passed over an agarose-avidin-biotin-PRKLYDY column. The column was washed with two column volumes of 100 nmol/L of the NH 2 -terminal rK5 peptide. Bound proteins were eluted with excess unlabeled rK5. Mass spectrometry analysis was used to determine the bound proteins.
The second method used to identify cell surface rK5 binding proteins was described previously (29) . Surface proteins on 4 Â 10 6 EaHy cells were labeled with NHS-biotin. The cells were washed and lysed (M-Per, Pierce). Cell lysates were mixed with S-tag K5 for 1 hour at room temperature. S-tag K5 bound proteins were precipitated with S-protein agarose (Pierce). Bound proteins were eluted with excess rK5 or excess PRKLYDY peptide. Eluted proteins were visualized with avidin-HRP and a chemiluminescent substrate. Mass spectroscopic analysis was used to identify the major protein bands.
Binding of rK5 to rGRP78 was measured using equilibrium dialysis (30) . In the top well of a 96-well equilibrium dialyzer (molecular weight cutoff 50 kDa, Harvard Apparatus, Holliston, MA), 150 AL of 10 nmol/L rGRP78 4664 www.aacrjournals.org were added. In the reciprocal (bottom) chamber, 150 AL of increasing concentrations from 0.1 to 50 nmol/L 3 HK5 were added. The chambers were shaken at room temperature for 72 hours. The total number of counts from both chambers after dialysis was compared with the number of counts remaining in the 3 HK5 chamber. RNA interference. RNA interference of GRP78 expression was induced with small interfering RNA (siRNA) directed against the GRP78 mRNA. Three different nucleotide siRNA primers were made that targeted human GRP78 mRNA sequence. The siRNAs started at position 139 (AAC GGC CGC GUG GAG AUC AUC), position 1,175 (AAG CUG UAG CGU AUG GUG CUG), and position 1,567 (AAG AUC ACA AUC ACC AAU GAC). A scrambled siRNA from position 1,567 was used as negative control (AAA UCA UAG CGU AUG GUG CUG). All oligonucleotides were from Dharmacon Research (Dharmacon RNA Technologies, Lafayette, CO).
EaHy or HT1080 cells were seeded at a density of 20,000 cells/cm 2 the day before transfection and were f40% confluent when they were transfected with 50 nmol/L positive or scramble oligonucleotides in LipofectAMINE 2000 (Invitrogen) and Opti-MEM (Life Technologies, Gaithersburg, MD) without serum or BSA. Before transfection, the cells were washed once with Opti-MEM. Transfection medium was maintained on cells for 3 hours and was then removed and substituted with complete medium. The reduction in GRP78 protein, 48 hours after transfection, was estimated by Western blot analysis (31) .
In selected studies, GRP78 siRNA-transfected or scrambled siRNAtransfected EaHy cells were grown in 96-well plates. The medium was changed and 3 HK5 in PBS was added to the cells at various concentrations. The cells were incubated at room temperature for 2 hours and then washed thoroughly. Cell counts were measured for bound 3 HK5 as described above. Data points were calculated from the average of triplicate samples.
Results
Recombinant kringle 5 and kringle 5 active site peptides inhibit endothelial cell activity. We have reported previously that rK5 has antiangiogenic activity in vitro, inhibiting bovine endothelial cell proliferation with an IC 50 value f50 nmol/L (15) . Here, we expand on those results using a yeast expressed rK5 (no detectable endotoxin) as well as synthetic K5 peptides to examine their effects on stimulated human endothelial cell proliferation, migration, and apoptosis assays. In these assays, rK5 inhibits stimulated human endothelial cell migration in a dose-dependent manner with an IC 50 value (Table 1 ) of 0.20 nmol/L. rK5 inhibited endothelial cell migration induced by a wide variety of inducers of angiogenesis, including aFGF, bFGF, IL-8, PDGF, TGF-h, and VEGF (Fig. 1A) . It was selective for endothelial cells because it failed to inhibit the migration of neutrophils and fibroblasts even when tested at concentrations up to 1,000-fold higher than that at which it inhibited endothelial cell migration (data not shown). rK5 also showed selectivity for inhibition of proliferation of stimulated endothelial cells and did not cause inhibition of tumor or primary cell proliferation at concentrations as high as 100 Amol/L ( Table 2) . Apoptosis of stimulated endothelial cells was induced by rK5 (Fig. 1B) in a dose-dependent manner, indicating that the binding of rK5 initiates a cell signaling cascade leading to cell death. . rK5 is pleiotropic for migration inhibition. A, HMVEC migration assay was done as described previously (26) . Growth factors were used, where indicated, at concentrations determined in preliminary experiments to give a migration response of f100 cells migrated per high-power field (Â100). Growth factors and concentrations used were aFGF (50 ng/mL), bFGF (15 ng/mL), IL-8 (40 ng/mL), TGF-h (1 pg/mL), VEGF (100 pg/mL), HGF (40 ng/mL), and PDGF (250 pg/mL). ABT-828 was 400 pmol/L, except in the cases of VEGF (rK5 = 100 pmol/L), PDGF (rK5 = 100 pmol/L), and HGF (rK5 = 10 pmol/L). Membranes were recovered, fixed, and stained and the number of cells that had migrated to the upper chamber per 10 high-power fields was counted. Background migration to DMEM + 0.1% BSA was subtracted and the data were reported as the number of cells migrated per 10 high-power fields (Â100).
Results are from triplicate experiments. *, P < 0.01. B, induction of stimulated HMVEC apoptosis by rK5. The rate of apoptosis was measured in HMVEC cells using a histone detection kit (23) . HMVECs were grown in 96-well plates. rK5 at various concentrations was added to plates and incubated overnight. Apoptosis was determined from triplicate samples and the apoptotic index was determined by dividing the absorbance from the treated cells by the absorbance from the untreated cells.
Kringle 5 Induces Apoptosis through GRP78
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To further explore the binding of rK5 to endothelial cell surfaces, linear peptides made from various regions of K5 were also tested in the endothelial cell migration assay (Table 1) . Peptides from the lysine-binding site of K5 displayed the highest activity at blocking stimulated endothelial cell migration. In fact, peptides PRKLYDY, KLYDY, and KLYD were equally potent compared with rK5 in the inhibition of migration of activated endothelial cells. However, peptides outside of this binding site pocket or tripeptides from the active site pocket were inactive at blocking endothelial cell migration. A NH 2 -terminally biotinylated PRKLYDY peptide and a S-protein-tagged rK5 were similarly active for the inhibition of stimulated endothelial cell migration. The bound proteins were eluted off with excess rK5. Lane A, eluent from K5 peptide column. Tryptic peptides from the isolated bands were analyzed by mass spectrometric analysis. The major protein was identified as GRP78. Lane B, molecular weight standards. B, avidin-HRP blots of biotinylated cell surface proteins isolated by affinity purification with immobilized S-tag K5. Surface proteins on 4 Â 10 6 endothelial cells were labeled with NHS-biotin. The cells were washed and lysed. The biotinylated surface proteins were isolated with avidin-agarose beads and eluted from the beads with excess streptavidin. Purified cell surface lysates were mixed with S-tag K5 for 1 hour at room temperature. S-tag K5 bound proteins were precipitated with S-protein agarose. Lane A, bound proteins were eluted with excess rK5; lane B, bound proteins were eluted with excess PRKLYDY peptide. Eluted proteins were visualized with avidin-HRP and a chemiluminescent substrate. Mass spectrometric analysis identified the bands as GRP78 and GRP94. IK5 (dog) HMVEC binding assay. Human rK5 potency is highly dependent on the extent of iodination because it contains a readily iodinated tyrosine in its binding sequence. Attempted mutations of this tyrosine to phenylalanine did not allow correct protein folding. However, dog K5 has a phenylalanine in this position naturally and is folded and active in our assays. We therefore relied on 125 IrK5 (dog) as a reagent.
125 IK5 (dog) was added to the wells and incubated at room temperature for 1 hour. After 1 hour, the cells were washed and the amount of 125 IK5 (dog) bound was counted. Scatchard plot analysis shows 125 IK5 (dog) bound with a K d of 0.8 nmol/L with f32,500 binding sites per cell. B, competition binding against 5 nmol/L 125 IK5 (dog). Anti-GRP78 or anti-K5 was added to HMVECs at various concentrations for 1 hour at room temperature. Cells were washed and the amount of 125 IK5 (dog) bound was counted. C, competition binding against 2 nmol/L 3 HK5. K5 peptides or a NH 2 -terminal antibody to GRP78 were added to HMVECs at various concentrations for 1 hour at room temperature. Cells were washed and the amount of 3 HK5 bound was counted.
These probes were important for the isolation of the cell surface receptor for rK5. Glucose-regulated protein 78 is an endothelial cell surface recombinant kringle 5 binding protein. To reduce the cell surface nonspecific protein binding that is often observed with proteins, an immobilized NH 2 -terminally biotinylated PRKLYDY peptide was used to isolate K5 binding proteins from endothelial cell surfaces. Bound proteins were then eluted with excess rK5. Mass spectrometric sequencing of tryptic peptides from the major protein band (f80 kDa; Fig. 2A ) revealed sequences corresponding to GRP78 (78 kDa). That GRP78 is a cell surface binding protein for rK5 was further confirmed by coprecipitation of biotinylated surface proteins with S-tagged K5. The major bound biotinylated proteins eluted with excess rK5 from immobilized S-tagged K5 (Fig. 2B) were identified by mass spectrometric analysis as GRP78 and GRP94.
Characterization of glucose-regulated protein 78 binding to recombinant kringle 5. The possibility that rK5 binds to GRP78 on endothelial cells was further explored by the examination of the amount of surface-expressed GRP78 compared with rK5 binding. Labeled K5 [ 125 IK5 (dog) or human 3 HK5] bound specifically to these cells with a K d of 0.8 nmol/L (Fig. 3A) , which is the same order of magnitude for rK5's inhibition of endothelial cell migration (0.25 nmol/L) and induction of endothelial cell apoptosis (1 nmol/L). A goat polyclonal antibody recognizing the NH 2 -terminal region of GRP78 inhibited the binding of 125 IK5 to proliferating endothelial cells in a concentration-dependent manner (Fig. 3B) . In comparison, a goat polyclonal antibody raised against the COOH-terminal region of GRP78 had no effect on cellular 125 IK5 binding. Competition binding with the K5 active site peptide, PRKLYDY (residues 80-86), but not the inactive rK5 NH 2 -terminal peptide, LLPDVETPSEED (residues 1-12), blocked 3 HK5 binding to endothelial cells in a concentration-dependent manner (Fig. 3C) . These results show that GRP78 and rK5 associate on the surface of proliferating endothelial cells. To investigate the specificity of GRP78/rK5 interaction, a mutant rK5(K82A) was used to compete with 3 HK5 binding to endothelial cell surfaces. Unlike rK5, the mutant rK5(K82A) at concentrations up to 500 nmol/L did not inhibit the binding of 3 HK5 or reduced the binding of a NH 2 -terminal GRP78 antibody on stimulated endothelial cell surfaces as determined by immunohistochemical analysis (Fig. 4) . The binding of rK5 to endothelial cells is dramatically reduced in starved, quiescent cells compared with VEGF/bFGF stimulated cells (Fig. 5A) . Analysis of GRP78 cell surface expression, using immunohistochemical techniques, displayed a readily detectable increase in GRP78 expression on stimulated endothelial cell surfaces compared with cells after starvation (Fig. 5B) . These results taken together indicate that the increase in rK5 binding to endothelial cell surfaces correlates with the amount of GRP78 expression on cells.
A NH 2 -terminal antibody to glucose-regulated protein 78 or reduced expression of glucose-regulated protein 78 inhibits the activity of recombinant kringle 5 on endothelial cells. The previous results suggest that GRP78 plays a role in the activity of rK5 on endothelial cells. A NH 2 -terminal GRP78 polyclonal antibody blocked the inhibition caused by rK5 on stimulated Figure 4 . rK5 but not rK5(K82A) mutant competes with anti-GRP78 antibody binding to EaHy cells. EaHy cells were grown overnight on glass slides. K5 or mutant rK5(K82A) at concentration of 500 nmol/L was added to the cells for 1 hour. Cells were washed and fixed. The surface GRP78 was visualized with a goat polyclonal GRP78 antibody using a 3,3V -diaminobenzidine system. Intensity of the brown stain indicates amount of GRP78 available for antibody binding. IK5 to HMVEC cells. Tritium-labeled rK5 was added to monolayers of 50,000 HMVEC cells that were either starved or stimulated for 16 hours by 15 ng/mL bFGF and 5 ng/mL VEGF in 96-well plates. The number of counts remaining bound to the cells after extensive washing determined the total amount of rK5 bound. B, immunohistochemical analysis of GRP78 on HMVEC cells at different times after activation with complete medium containing VEGF and bFGF. Cells were starved overnight with medium alone. Complete medium, containing 10% fetal bovine serum + 15 ng/mL bFGF and 5 ng/mL VEGF, was added to the cells for immunohistochemical analysis. GRP78 bound antibody was visualized with HRP-reactive substrate visualized by a brown color.
www.aacrjournals.org endothelial cell proliferation in a concentration-dependent manner (Fig. 6A) , whereas antibodies to unrelated proteins, HSP70, fibrin, and a v h 3 , had no effect, except at very high concentrations (Fig. 6B) . The same NH 2 -terminal GRP78 antibody also blocked the rK5-induced inhibition of endothelial cell migration (Fig. 6C ) and rK5-induced apoptosis of endothelial cells (Fig. 6D) . The expression of GRP78 on endothelial cells was significantly reduced by the transfection of a siRNA for GRP78 but not by the transfection of a scrambled siRNA (Fig. 7A) . The binding of rK5 to GRP78 siRNAtransfected HMVEC cells was very low compared with the binding of rK5 to scrambled siRNA-transfected cells (Fig. 7B) . These results confirm the requirement for GRP78 expression for rK5 inhibitory activity on endothelial cells.
Direct binding of recombinant kringle 5 with recombinant glucose-regulated protein 78. To directly observe the binding of GRP78 and rK5, we used yeast-expressed recombinant human GRP78 (rGRP78) protein and 3 HK5. Equilibrium dialysis of rGRP78 and 3 HK5 revealed direct binding of rGRP78 and rK5 in a concentration-dependent manner with a K d of f0.7 nmol/L (Fig. 8A) . This binding could be blocked by the addition of unlabeled rK5 (Fig. 8B) . However, the rK5(K82A) mutant in concentrations up to 25-fold excess of GRP78 concentration did not block binding, confirming that GRP78 binds with high affinity and specificity to rK5.
Recombinant kringle 5 causes apoptosis of hypoxic tumor cells. Our results show that the inhibitory activity of rK5 on endothelial cells is mediated through cell surface GRP78. We have also shown that K5 does not affect tumor cell proliferation in normal conditions in vitro (Table 2 ). However, published data indicate that tumor cells up-regulate surface GRP78 expression under stressed conditions (32) . When hypoxia and/or the addition of cytotoxic stress are applied to tumor cells, an apoptosisresistant phenotype often emerges. This resistance has been linked to GRP78 surface expression (32) . We examined the effect of rK5 on tumor cells under stressed hypoxic conditions. Hypoxia increased GRP78 expression on HT1080 human fibrosarcoma cells at least 4-fold (Fig. 9A) . When rK5 was added to these cells under hypoxic conditions (5% CO 2 , 95% N 2 ), there was a >2-fold increase in apoptosis within 24 hours (Fig. 9B) , whereas hypoxia alone or the addition of rK5 without hypoxia had no significant effect on cellular apoptosis. To determine if the proapoptotic effect of rK5 on hypoxic tumor cells was specific to HT1080 cells, we tested apoptosis rates for various tumor cell lines exposed to rK5 under hypoxia. As seen in Fig. 9B, rK5 induced apoptosis of EaHy endothelial cells with and without hypoxia, supporting previous data where the rK5 receptor was up-regulated during endothelial cell stimulation in normoxic conditions. However, rK5 induced apoptosis in seven of nine tumor cell lines tested only under hypoxic conditions. The two tumor cells lines that did not respond to rK5 under hypoxic conditions were Lewis lung and PC-3. For a possible explanation, we examined GRP78 surface expression on Figure 6 . GRP78 antibody inhibits rK5 cellular activity. A, anti-GRP78 blocks K5's inhibition of HMVEC proliferation. HMVEC cellular proliferation assay was done with 10,000 cells added to each well of a 96-well plate. After the cells had attached, complete medium containing VEGF (5 ng/mL) and bFGF (15 ng/mL) along with rK5 with or without the GRP78 antibody was also added. The cells were grown for 72 hours. 3-[4,5,Dimethylthiazol-2-yl]-5-[3-carboxymethoxy-phenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt assay was used to determine the number of live cells. Results were determined from triplicate samples. B, nonspecific antibodies do not block rK5's inhibition of HMVEC proliferation. Various antibodies (100 Ag/mL) to unrelated proteins were added to HMVEC cellular proliferation assays containing 100 ng/mL K5 as mentioned above. Inhibition of cellular proliferation was determined from quadruplicate tests. C, anti-GRP78 blocks rK5's inhibition of stimulated HMVEC migration. Stimulated HMVEC cell chemotaxis toward VEGF (5 ng/mL) was done in 96-well plates for 4 hours at room temperature. Casein-AM prelabeled HMVEC cells that had migrated to the bottom of the membrane were measured by fluorescence. D, anti-GRP78 inhibits the increase in HMVEC cellular apoptosis caused by rK5. The rate of apoptosis was measured in HMVEC cells using a histone detection kit. HMVECs were grown in 96-well plates. rK5 and an antibody to GRP78 were added to plates and incubated overnight. Apoptosis was determined from triplicate samples and the apoptotic index was determined by dividing the absorbance from the treated cells by the absorbance from the untreated cells.
PC-3 cells under hypoxic conditions. Immunohistochemical analysis of PC-3 and Lewis lung cells showed no increase in GRP78 expression under hypoxia (data not shown), which is in sharp contrast with the stress-induced GRP78 expression on HT1080 cells. To make the expression of GRP78 on HT1080 cells appear more like PC-3 cells, we used a siRNA to GRP78 for the knockdown of protein expression. There was an f90% decrease in GRP78 expression in transfected HT1080 (GRP78 À ) cells (data not shown), which was very similar to the siRNA knockdown of GRP78 expression we observed in HMVECs (Fig. 7A ). This decrease in GRP78 protein expression significantly eliminated the proapoptotic activity of rK5 on hypoxic HT1080 (GRP78 À ) cells (Fig. 9C) . However, rK5 significantly induced apoptosis of the hypoxic HT1080 cells transfected with scrambled siRNA and control nontransfected cells. These data show the necessary GRP78 expression for rK5 induction of apoptosis on tumor cells.
Recent reports have shown that the ATPase domain of GRP78 binds to procaspase-7, blocking its activation and decreasing stressinduced cellular apoptosis. Our nuclear magnetic resonance studies with a recombinant GRP78 ATPase domain show direct binding of rK5 with the ATPase domain of GRP78. 4 We have also shown that the GRP78 ATPase domain on stressed tumor cells is extracellular (Fig. 9A) . If rK5 is then internalized and competes with procaspase-7 for GRP78 binding, then stressed tumor cells treated with rK5
should show an increase in caspase-7 activity compared with untreated cells. Our data (Fig. 10) show a significant increase in caspase-7 activities in HT1080 cells when treated with rK5 and hypoxia, consistent with this hypothesis.
Discussion
These results show that rK5 binds with high affinity to endothelial cells through an interaction on the lysine-binding site of rK5 and GRP78. The inhibition of this interaction with an antibody against GRP78 blocks the induction of endothelial cell apoptosis. Exposure of quiescent endothelial cells to VEGF or of tumor cells to a stress-like hypoxia increases surface-expressed GRP78 and as such increases the number of binding sites for rK5. Peptides from the lysine-binding site of rK5 potently compete with rK5 cellular binding and induce endothelial cell apoptosis. As further evidence that the rK5 lysine-binding site is important for the binding of rK5 to GRP78, the Lys 82 of K5 was mutated to alanine [rK5(K82A)], which abolished f90% of its ability to inhibit in vitro migration, although the kringle was still correctly folded as 3 HK5 was added to one side of an equilibrium chamber at concentrations from 0.1 to 3 nmol/L. GRP78 (2 nmol/L) was added to the other side of the chamber with a 50,000-kDa MWCO filter between.
3 HK5 was allowed to equilibrate to both sides of the chamber for 72 hours at room temperature. A, GRP78 and rK5 bind with high affinity. The amount of 3 HK5 on the GRP78 side of the chamber was compared with chamber with 3 HK5 alone to obtain the bound versus free rK5 distribution. B, mutant rK5(K82A) does not compete with binding of rK5 and rGRP78. Competition binding dialysis was done with 2 nmol/L GRP78 and 2 nmol/L 3 HK5 using rK5(K82A) mutant and unlabeled rK5 at various concentrations from 0.5 to 50 nmol/L. The amount of 3 HK5 on both sides of the chamber was measured after 72 hours and compared with the control. 4 In preparation.
determined by nuclear magnetic resonance analysis (22) . This mutant K5(K82A) did not compete with 3 HK5 binding to endothelial cells or with direct binding of 3 HK5 to recombinant GRP78 (K d = 0.25 nmol/L). To further elucidate this binding, immunohistochemical analysis of cells with anti-GRP78 were examined with and without K5 or K5(K82A) mutant. Wild-type rK5 reduced the binding of the GRP78 antibody to cells, but the K5(K82A) mutant had no effect on GRP78 antibody binding. This specificity of binding on cell surfaces was also examined using the siRNA for GRP78 on endothelial cells. When siRNA transfection reduced the GRP78 protein concentration by f90% on EaHy and HT1080 cells, there was greatly reduced binding of 3 HK5 to cell surfaces. These observations show that the effects of rK5 on proliferating endothelial cells require direct, specific, high-affinity binding to GRP78.
This conclusion is not excluded by the results of a previous study reporting that the K5 endothelial cell surface binding protein was voltage-dependent anion channel (VDAC; ref. 33) . That study used confluent, static monolayers of endothelial cells to examine rK5 binding. However, our findings show that under confluent conditions GRP78 is minimally exposed on the endothelial cell surface; hence, other binding proteins may play a more prominent role for rK5 binding under these static growth conditions. Our studies were carried out under subconfluent conditions. There are also reports that show VDAC is chaperoned to cell surfaces by heat shock or glucose-regulated proteins. It is possible that rK5 binds to GRP78, which is associated with VDAC on cell surfaces (34) . VDAC siRNA knockdown experiments are under way to determine if rK5 binding to GRP78 may depend on VDAC expression. However, our results challenge the direct binding of rK5 to VDAC because of the tight binding of rK5 to GRP78 (K d = 0.25 nmol/L) compared with the reported rK5 binding to VDAC (K d = 28 nmol/L). A recent study showing that rK5 is more effective on hypoxic endothelial cells supports our data of increased rK5 surface binding to endothelial cells with stress and supports our finding of increased apoptosis by rK5 on hypoxic tumor cells. The GRP78 antibody and GRP78 siRNA provide nearly quantitative inhibition of rK5 binding to endothelial cell surfaces providing additional evidence for GRP78 as the dominant rK5 binding protein.
In addition to identifying and establishing the importance of an uncharacterized endothelial cell binding protein for rK5, our results also show that rK5 directly induces tumor cell apoptosis under stressed conditions. Reports have shown that the induction of GRP78 is critical for tumor cells to maintain viability during stress-like hypoxia and glucose deprivation. In addition, the induction of tumor cell surface-expressed GRP78 by hypoxic conditions has been linked to resistance to cytotoxic or radiation therapy in vitro and in vivo (35) . Surface-expressed GRP78 was induced by hypoxia on the surface of 8 of the 10 tumor cell lines tested here. Under these conditions, rK5 had a very potent proapoptotic effect on all eight of the hypoxia-stressed tumor cell lines that induced surface-expressed GRP78. The two tumor lines, PC-3 and Lewis lung, on which rK5 had no proapoptotic effect, did not up-regulate GRP78 under hypoxic conditions. These results show the selectivity of rK5 for most stressed tumor cells and activated endothelial cells but not for normal or quiescent endothelial cells.
The identification of GRP78 as an endothelial and tumor cellbinding site required for the antitumor and antiangiogenic activity of rK5 raises several questions concerning the mechanism by which rK5 induces cellular apoptosis. Although rK5 binds to GRP78, there is not a predicted transmembrane domain in GRP78 to transfer signal to the cytosol. However, published reports indicate that GRP78 may protect cells from apoptosis during stress by blocking procaspase-7 activation (36). We hypothesize that rK5 binds to Figure 9 . rK5 inhibited proliferation and increased apoptosis of tumor cells in hypoxic conditions by the up-regulation of GRP78. A, HT1080 fibrosarcoma tumor cells were plated on slides overnight with complete medium. Control slides were put in the incubator at 5% CO 2 at 37jC. The other slide of cells was put in a hypoxic chamber with 95% N 2 , 5% CO 2 at 37jC for 24 hours. GRP78 on the cell surface was detected by immunohistochemical analysis with a polyclonal antibody to GRP78 conjugated to HRP. The GRP78 was visualized with the 3, 3V -diaminobenzidine reagent displaying a brown color. B, cells were plated in 96-well plates overnight. Half the plates were put in hypoxic chambers overnight at 37jC with and without 500 nmol/L rK5. Increased apoptosis was shown by an ELISA technique that measures the number of nucleosome fragments. The apoptotic index was calculated from the apoptosis rate of control cells (without K5 and with or without hypoxia). The samples were run in quadruplicate. C, HT1080 tumor cells were transfected with a siRNA to GRP78. The transfected cells were plated in 96-well plates and placed at 5% CO 2 at 37jC. rK5 (500 nmol/L) was added to the cells and half were incubated in an hypoxic chamber with 95% N 2 , 5% CO 2 at 37jC and half were incubated at 5% CO 2 at 37jC for 24 hours. Apoptosis was shown by an ELISA technique mentioned above. Samples were run in quadruplicate. *, P < 0.01.
GRP78 and is endocytosed into the cell where rK5 blocks GRP78 binding to procaspase-7. Evidence supporting this hypothesis is shown by our finding that when rK5 is added to stressed endothelial cells or stressed HT1080 cells caspase-7 activity is increased at least 2-fold within 2 hours. We also show that the cell surface concentration of GRP78 is greatly reduced within a few hours after rK5 binding (Fig. 10B) . Expression of recombinant procaspase-7 is under way, which will help to determine if rK5 can inhibit the binding rGRP78 to procaspase-7. Although rK5 could block the protection of procaspase-7 leading to active caspase-7 generation, the appearance of other caspases within the cell necessary to activate caspase-7 argues that additional mechanisms for rK5's antiangiogenic activity exist.
In summary, we have shown that an interaction between rK5 and GRP78 on stimulated endothelial and stressed tumor cells underlies the proapoptotic activity of rK5. To our knowledge, this is the first evidence that an antiangiogenic compound is effective directly against stressed tumor cells. Finally, we predict that a two-stage inhibition of in vivo tumor growth by rK5 could exist. First, rK5 would induce apoptosis in activated tumor endothelial cells. Subsequently, the consequent hypoxia would cause tumor cells to present surface-expressed GRP78, allowing rK5 to enhance tumor cell apoptosis. The second state of rK5 action could go beyond tumor stasis and possibly lead to tumor regression. Further efforts to characterize the biology of GRP78 as well as the binding interaction between GRP78 and rK5 may yield insight into both the regulation of angiogenesis and the survival of hypoxic tumor cells. These findings could lead to the development of novel agents targeted toward pathologic angiogenesis and tumor cell survival.
